浙江海正生物材料股份有限公司（以下简称"公司"）第六届董事会第二十六次会议 审议了《关于公司募集资金半年度存放与实际使用情况的专项报告》，公司董事会已向我 们提交了有关资料，我们在审阅有关资料的同时，就相关问题向公司有关部门和人员进行 了询问。根据《公司章程》及《独立董事工作制度》的规定，基于独立判断，现就上述事 项发表如下独立意见： 《关于公司募集资金半年度存放与实际使用情况的专项报告》真实、准确、完整地反 映了 2023 年上半年公司募集资金的存放、使用与管理情况，募集资金实际使用情况与公 司信息披露情况一致，符合《上市公司监管指引第 2 号——上市公司募集资金管理和使用 的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法 律法规的相关规定，不存在违规存放和使用募集资金的行为，亦不存在变相改变募集资金 用途和损害股东特别是中小股东利益的情形。因此，我们同意公司编制的《关于公司募集 资金半年度存放与实际使用情况的专项报告》。 独立董事：王建祥、沈书豪、彭松、刘冉 二〇二三年八月十一日 海正生材独董意见 2023-3 号 浙江海正生物材料股份有限公司独立董事 关于第六届董事会第 ...

证券代码：688203 证券简称：海正生材 公告编号：2023-20 浙江海正生物材料股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 投资者可于 2023 年 08 月 10 日(星期四) 至 08 月 16 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券部邮箱 hisunpla@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江海正生物材料股份有限公司（以下简称"公司"）将于 2023 年 8 月 15 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年上半年的经营成果、财务状况，公司计划于 2023 年 08 月 17 日下午 15:00-16:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以网 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥142,795,235.72, representing a decrease of 18.55% compared to the same period last year[5] - The net profit attributable to shareholders of the listed company was ¥4,160,245.29, down 58.14% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥3,445,631.20, a decline of 62.71% compared to the previous year[5] - The basic earnings per share for the period was ¥0.02, a decrease of 71.43% year-on-year[6] - Total operating revenue for Q1 2023 was ¥142,795,235.72, a decrease of 18.6% compared to ¥175,316,895.20 in Q1 2022[18] - Net profit for Q1 2023 was ¥4,154,513.72, a decline of 58.2% from ¥9,934,648.54 in Q1 2022[19] - Basic earnings per share for Q1 2023 were ¥0.02, compared to ¥0.07 in Q1 2022, reflecting a 71.4% decrease[20] - The company’s total comprehensive income for Q1 2023 was ¥4,154,513.72, down from ¥9,934,648.54 in Q1 2022[20] Research and Development - The total R&D investment amounted to ¥5,428,464.61, an increase of 75.45% compared to the same period last year[6] - The proportion of R&D investment to operating revenue was 3.80%, up 2.04 percentage points year-on-year[6] - Research and development expenses increased to ¥5,428,464.61 in Q1 2023, up 75.4% from ¥3,094,023.51 in Q1 2022[18] Cash Flow and Liquidity - The net cash flow from operating activities was ¥37,619,112.97, down 15.38% compared to the previous year[6] - Cash flow from operating activities for Q1 2023 was ¥37,619,112.97, down 15.4% from ¥44,455,687.69 in Q1 2022[23] - The company recorded a net cash outflow from investing activities of -¥71,787,756.77 in Q1 2023, compared to -¥56,216,787.63 in Q1 2022[23] - The net cash flow from financing activities was -$3,675,969.36, indicating a significant outflow compared to the previous period's -$15,395,767.99[24] - The total cash and cash equivalents at the end of the period decreased to $879,323,074.53 from $917,893,087.61 at the beginning of the period, reflecting a net decrease of $38,570,013.08[24] - The impact of exchange rate changes on cash and cash equivalents was -$725,399.92, which is a notable change from -$302,573.33 in the previous period[24] Assets and Liabilities - Total assets at the end of the period were ¥1,972,695,944.93, an increase of 2.34% from the end of the previous year[6] - As of March 31, 2023, the total assets amounted to CNY 1,972,695,944.93, an increase from CNY 1,927,583,851.08 as of December 31, 2022, reflecting a growth of approximately 2.3%[15] - The total current assets decreased to CNY 1,074,838,907.36 from CNY 1,102,374,248.64, representing a decline of about 2.5%[16] - The company's cash and cash equivalents stood at CNY 896,119,710.09, down from CNY 938,487,988.19, indicating a decrease of approximately 4.5%[15] - The total liabilities increased to CNY 516,648,127.34 from CNY 475,690,547.21, marking an increase of about 8.6%[17] - The company's equity increased to CNY 1,456,047,817.59, up from CNY 1,451,893,303.87, showing a slight growth of approximately 0.3%[17] - The accounts receivable rose significantly to CNY 31,352,219.98 from CNY 8,302,121.89, reflecting an increase of approximately 277%[15] - Inventory decreased to CNY 122,027,995.45 from CNY 135,942,269.61, indicating a decline of about 10.3%[16] - The company reported a total of CNY 348,733,155.86 in current liabilities, an increase from CNY 307,370,843.59, which is an increase of approximately 13.5%[17] - The long-term borrowings remained stable at CNY 127,170,513.00, slightly down from CNY 127,314,504.50, showing a decrease of about 0.1%[17] - The company’s retained earnings increased to CNY 41,912,462.43 from CNY 37,752,217.14, reflecting a growth of approximately 11.4%[17] Operating Costs - Total operating costs for Q1 2023 were ¥135,987,052.05, down 16.6% from ¥163,128,824.90 in Q1 2022[18]

证券代码：688203 证券简称：海正生材 公告编号：2023-13 浙江海正生物材料股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： （网址：http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2023 年 03 月 16 日(星期四) 至 03 月 22 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司证券部邮箱 hisunpla@hisunpharm.com 进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 浙江海正生物材料股份有限公司（以下简称"公司"）已于 2023 年 3 月 14 日发布公司 2022 年年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况，公司计划于 2023 年 03 月 23 日下午 15:00-16:00 举 行 2022 年度业绩说明会，就投资者关心的问题进行交流。 一、 说明会类型 ...

Financial Performance - The company plans to distribute a cash dividend of 0.7 RMB per 10 shares, totaling approximately 14,187,464.76 RMB, which represents 30.17% of the net profit attributable to shareholders for 2022[6]. - The company has achieved a significant increase in its net profit, with a year-on-year growth of 30.17%[6]. - The company's operating revenue for 2022 was CNY 605,432,444.66, representing a 3.49% increase from CNY 585,005,074.82 in 2021[21]. - Net profit attributable to shareholders increased by 33.33% to CNY 47,031,528.75 from CNY 35,274,798.95 in the previous year[21]. - The cash flow from operating activities surged by 91.27% to CNY 136,145,267.65 compared to CNY 71,178,724.03 in 2021[21]. - Basic earnings per share rose by 21.74% to CNY 0.28, while diluted earnings per share also increased by the same percentage[22]. - The company's total assets grew by 62.90% to CNY 1,927,583,851.08 from CNY 1,183,273,592.28 in 2021[21]. - The net asset attributable to shareholders increased by 122.00% to CNY 1,451,881,774.29 from CNY 653,989,081.86 in 2021[21]. - The company reported a decrease in the weighted average return on equity to 5.07%, down from 5.54% in the previous year[22]. - The company achieved an operating income of 605 million RMB in 2022, showing a slight increase compared to the previous year, despite a decline in terminal market demand and product prices[88]. - The net profit attributable to the parent company was 47.03 million RMB, representing a 33.33% increase year-on-year, primarily due to government subsidies and non-recurring gains[88]. - The total assets of the company increased by 744.31 million RMB at the end of 2022, mainly due to an increase in current assets from the IPO fundraising[88]. Research and Development - Research and development expenses accounted for 3.14% of operating revenue, up from 2.42% in 2021, indicating a focus on innovation[22]. - The company invested CNY 19.03 million in R&D during the reporting period, an increase of nearly 35% compared to the previous year, and added 14 new R&D projects[33]. - The company has achieved a 34.40% increase in research and development (R&D) investment, totaling ¥19,025,727.06, compared to ¥14,155,810.66 in the previous year[65]. - The R&D model includes forward-looking, demand-responsive, and process improvement types, focusing on new technologies and customer-specific product solutions[49][50]. - The company has developed core technologies covering all key processes in PLA production, reducing reliance on imported raw materials[55]. - The company is focusing on high optical purity and molecular weight distribution as key technical development directions in the PLA industry[57][58]. - The company has obtained 4 new invention patents during the reporting period, bringing the total number of granted patents to 27[62][63]. - The company has developed core technologies covering key production processes of PLA, including multi-effect continuous evaporation and self-made high-efficiency cyclization technology, both of which are in mass production[60]. Market Position and Strategy - The company maintains a leading market position domestically while establishing influential partnerships in Europe and the United States[34]. - The company is actively developing new products and technologies to enhance its competitive edge in the PLA market[38]. - The company is currently constructing a 150,000-ton PLA project, which is progressing according to government planning requirements[35]. - The company aims to achieve a competitive position with international leaders through capacity expansion projects and technological advancements[56]. - The company plans to expand its market share in polylactic acid products, particularly in straws and film bags, despite challenges in export demand[94]. - The company is exploring market expansion opportunities through innovative product development and strategic partnerships[68]. - The company is currently a leader in the domestic polylactic acid (PLA) industry in terms of technology, production capacity, output, and sales, and aims to match the scale of international leaders within 2-3 years[56]. Risks and Challenges - The company has outlined various risks in its operations and corresponding countermeasures in the report[4]. - The company faces risks related to core technology leakage, which could undermine its competitive advantage if not properly managed[78]. - The company is at risk of technological development lagging behind market demands, which could affect its competitiveness if it fails to innovate[78]. - The concentration of suppliers poses a risk to the company's operations, as any adverse changes in supplier relationships could impact production and costs[79]. - The company faces risks related to the concentration of major customers, which could negatively impact operations if new customer acquisition does not meet expectations[81]. - There is a risk of increased production costs due to potential significant price hikes in high-purity lactic acid, a key raw material for polylactic acid production[80]. - The competitive landscape is intensifying, with both domestic and international players increasing their polylactic acid production capacity, which may lead to price declines[82]. Governance and Compliance - The company has a complete governance structure, with 11 board members, including 4 independent directors, ensuring compliance with legal requirements[127]. - The company has established a comprehensive internal control management system to ensure compliance and protect shareholder rights[166]. - The company has not reported any major deficiencies in internal control during the reporting period, indicating effective governance[166]. - The company has established a governance structure that ensures the protection of shareholder and creditor rights, complying with relevant laws and regulations[188]. - The company has conducted 4 shareholder meetings in the reporting period, ensuring compliance with relevant regulations[127]. - The company approved all proposals during the 2022 annual shareholder meetings, with no dissenting opinions noted[132]. Environmental and Social Responsibility - The company invested CNY 681.87 million in environmental protection during the reporting period, indicating a commitment to sustainability[169]. - The company has established a comprehensive environmental protection management system, issuing 23 environmental-related regulations during the reporting period[182]. - The company has implemented measures to optimize production processes and equipment, resulting in stable overall energy consumption and reduced greenhouse gas emissions[183]. - The company has established a unified leadership and hierarchical management system for ecological and environmental responsibilities[184]. - The company actively engages in community service activities, reflecting its commitment to social responsibility[194]. - The company has established a dedicated investor relations management team to ensure accurate and timely information disclosure, enhancing communication with investors[196]. Employee and Compensation - The total remuneration for the chairman was reported at 0 million yuan, while the general manager received 103.82 million yuan[137]. - The total remuneration for all directors, supervisors, and senior management personnel at the end of the reporting period amounted to 3.70 million RMB[149]. - The total remuneration for core technical personnel at the end of the reporting period was 3.44 million RMB[149]. - The company adheres to a compensation policy that prioritizes economic efficiency while ensuring fairness, linking employee salaries to company performance and individual achievements[158]. - The company emphasizes the importance of employee training, implementing annual training plans to enhance overall employee quality and professional skills[159].

2022 年第三季度报告 证券代码：688203 证券简称：海正生材 浙江海正生物材料股份有限公司 2022 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告期 末比上年同期 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 增减变动幅度 | | | | 动幅度(%) | | (%) | | 营业收入 | 176,166,819.01 | 8.14 | 478,784,762.45 | 11.73 ...